Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20
While not perfect, the latest Phase II data for the stromal depleting agent PEGPH20 give cause for optimism for hyaluronan as a biomarker in pancreatic cancer and for Halozyme's Phase III strategy.
You may also be interested in...
Bristol will pay $105m up front and as much as $1.76bn in milestone fees to use the Enhanze technology in drugs against up to 11 immuno-oncology targets. Also, Roche will pay up to $190m to add a target to an existing partnership.
Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.
ASCO reflected diverse lay of the land for the challenging development space, with new drugs coming from Merrimack, Halozyme, Threshold and a range of immunotherapy combinations. Meanwhile, Celgene’s Abraxane appears to be on blockbuster track.